MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Closed

2.43 -3.19

Overview

Share price change

24h

Current

Min

2.36

Max

2.52

Key metrics

By Trading Economics

Income

-6.4M

-53M

Sales

-9.6M

47M

Profit margin

-112.813

Employees

580

EBITDA

-28M

-49M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+82.54% upside

Dividends

By Dow Jones

Next Earnings

6 Aug 2025

Market Stats

By TradingEconomics

Market Cap

223M

997M

Previous open

5.62

Previous close

2.43

Technical Score

By Trading Central

Confidence

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Chart

Past performance is not a reliable indicator of future results.

Related News

17 Jul 2025, 23:34 UTC

Acquisitions, Mergers, Takeovers

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 Jul 2025, 21:14 UTC

Acquisitions, Mergers, Takeovers

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 Jul 2025, 21:04 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 Jul 2025, 23:43 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 Jul 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 Jul 2025, 22:47 UTC

Acquisitions, Mergers, Takeovers

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 Jul 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 Jul 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 Jul 2025, 22:43 UTC

Acquisitions, Mergers, Takeovers

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 Jul 2025, 22:43 UTC

Acquisitions, Mergers, Takeovers

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 Jul 2025, 22:40 UTC

Acquisitions, Mergers, Takeovers

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 Jul 2025, 22:40 UTC

Acquisitions, Mergers, Takeovers

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 Jul 2025, 22:30 UTC

Market Talk
Earnings

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 Jul 2025, 22:20 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

17 Jul 2025, 22:20 UTC

Market Talk
Earnings

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 Jul 2025, 22:04 UTC

Market Talk
Earnings

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 Jul 2025, 22:03 UTC

Acquisitions, Mergers, Takeovers

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 Jul 2025, 21:58 UTC

Market Talk
Earnings

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 Jul 2025, 21:57 UTC

Earnings

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 Jul 2025, 21:47 UTC

Earnings

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 Jul 2025, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 Jul 2025, 21:45 UTC

Market Talk

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 Jul 2025, 21:38 UTC

Acquisitions, Mergers, Takeovers

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 Jul 2025, 21:22 UTC

Acquisitions, Mergers, Takeovers

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 Jul 2025, 21:05 UTC

Earnings

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 Jul 2025, 21:04 UTC

Acquisitions, Mergers, Takeovers

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 Jul 2025, 21:02 UTC

Acquisitions, Mergers, Takeovers

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 Jul 2025, 20:59 UTC

Acquisitions, Mergers, Takeovers

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 Jul 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

17 Jul 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Peer Comparison

Price change

Maravai LifeSciences Holdings Inc (Class A) Forecast

Price Target

By TipRanks

82.54% upside

12 Months Forecast

Average 4.6 USD  82.54%

High 7 USD

Low 2 USD

Based on 7 Wall Street analysts offering 12 month price targets forMaravai LifeSciences Holdings Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

7 ratings

4

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

2.02 / 2.115Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

No Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.